Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

DAWN·NASDAQ

$21.53

+0.0000%
HealthcareBiotechnology

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

At a Glance

Live Snapshot
Market Cap$2.22B
EPS-1.0400
P/E Ratio-20.70
Earnings Date05/13/2026

dawn

Total Other Income Expenses Net

Last Annual Value

18.45M

3-Year CAGR

57%

5-Year CAGR

21%

10-Year CAGR

27%

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. Competitors Analysis of Total Other Income Expenses Net

DAWN · NASDAQ
CompanyTotal Other Income Expenses Net
CAGR 3Y
CAGR 5Y
CAGR 10Y
18.45M
2.5%N/AN/A 
-31.95M
N/AN/AN/A
17.30M
19.5%206.5%N/A
12.81M
5.8%N/AN/A
11.23M
28.8%N/AN/A
ARVN logo
Arvinas, Inc.
NASDAQ:ARVN
34.40M
-0.7%N/A32.7%
ERAS logo
Erasca, Inc.
NASDAQ:ERAS
6.86M
-25.3%26.5%N/A
30.25M
-18.6%-25.2%N/A
14.80M
68.7%N/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
5.48M
9.3%22.4%79.5%
Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. Fair Value Envelope

DAWN · NASDAQ

Our analysis suggests that DAWN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $21.53, this represents a potential HIDDEN relative to our calculated worth for Day One Biopharmaceuticals, Inc..

Intrinsic Value
Current Price: $21.53